$STX

Lee James CI sold $7.2M of STX

Lee James CI (EVP & CLO) sold 9,013 shares of Seagate Technology Holdings plc (STX) at an average of $794.84 ($774.84–$816.96, $7.16M total) across 29 trades on 2026-08-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lee James CI
Published Aug 26, 2026, 8:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 9:53 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STX
Bearish
medium confidence
Mentioned
$STX
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STXBearishLow
01

Why it matters

The disclosed sale reduces insider ownership dramatically, which may be interpreted as a bearish signal.

02

Market read

First‑report insider sell of $7.2M by a senior executive; traders may adjust short positions or monitor price reaction.

03

What to watch

Potential tax‑loss harvesting or pre‑planned diversification via the 10b5‑1 plan.

Relevance 5/10Novelty 8/10Timing: filed 2026-08-26

Background

Form 4 filings provide the first public disclosure of insider transactions, offering fresh data for traders.

Company-level read

Ticker impact

$STXBearishMedium confidence
Context

SEC Form 4 disclosed EVP & CLO Lee James sold 9,013 shares for $7.2M via a 10b5‑1 plan, reducing his stake to 347 shares.

Expected impact

Potential short‑term pressure on STX price, especially if market perceives the sale as a lack of confidence.

Evidence & confidence

C‑suite insider sale of multi‑million dollars is material; however, the remaining holding is small, limiting long‑term impact.

Market effects

May prompt scrutiny of the broader data‑storage sector for insider sentiment.

Limited to U.S. markets where STX trades.

Minimal global effect beyond investors tracking large‑cap hardware stocks.

Counterpoint

The sale could be routine portfolio rebalancing unrelated to company fundamentals.

Key entities

  • Seagate Technology Holdings plc

    Global data storage solutions provider.

  • Lee James

    Executive Vice President & Chief Legal Officer of Seagate.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVDAHighAI 9/10

Markets News, Aug. 27, 2026: Nvidia Stock Powers Higher After Earnings, Driving Tech Gains; Nasdaq Closes Sharply Higher

Nvidia (NVDA) reported strong Q2 earnings and raised Q3 revenue guidance to $108B, driving its stock up 9% and boosting tech sector gains. Nasdaq, S&P 500, and Dow closed higher. Other notable movers include Okta (OKTA) +29%, Salesforce (CRM) +23%, and CrowdStrike (CRWD) +20%. Corporate profits surged $400B in Q2, partly due to $71B in tariff refunds.

$STXMed

Moody’s upgrades Seagate Data rating on AI demand strength

Moody's upgraded Seagate Data's corporate family rating to Ba1 from Ba2, citing AI-driven demand for high-capacity HDDs. The agency expects revenues to grow over 30% annually, reaching $20B, and debt to EBITDA to fall below 0.5x. Seagate faces risks from revenue concentration and pricing pressures. The company had $1.7B in cash and access to a $1.3B credit facility as of July 2026.

$MRNAHighAI 8/10

3 Stocks Soared, 3 Stocks Slumped

Moderna (MRNA) surged 176.97% to $174.38 after reporting positive trial results for a cancer therapy with Merck (MRK). Estee Lauder (EL) rose 16% to $98.01 with revenue up 6.5% Y/Y. MicroStrategy (MSTR) gained 12.68% as Bitcoin prices rose. Nebius (NBIS) fell 10% after a $4.5B convertible note offering. Seagate (STX) dropped 8% to $832.56.

$STXMed

REG - Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US

Shield Therapeutics (STX) will take full control of ACCRUFeR® in the US from Viatris by September 30, 2026. The deal is expected to boost Shield's profitability and growth, with no upfront payments to Viatris. Shield will pay royalties on US net sales, ranging from high single digits to mid-teens over five years, and retain all gross profits from US sales. The transaction is anticipated to enhance Shield's financial profile and support its path to sustained profitability.